ONO 4641 in MS –an oral investigational sphingosine-1-phosphate (S1P) receptor modulator originally disovered and developed by Ono Pharmaceutical.
– Cilengitide is the first in a new class of investigational targeted anti-cancer therapies - the integrin inhibitors - to reach Phase III clinical development. Cilengitide is thought to control tumor growth by working in two ways: through attacking the tumor cells directly in a targeted manner and through starving tumor cells by stopping the formation of new blood vessels (angiogenesis) that feed the tumor. Two Phase II trials are underway: one in non-small cell lung cancer, another in squamous cell carcinoma of the head and neck.
Anti-integrin monoclonal antibody (DI17E6) in colorectal and metastatic prostate cancer – a monoclonal antibody that is thought to target certain integrins expressed on tumor and endothelial cells. DI17E6 is in Phase II development to investigate its potential safety and efficacy in colorectal cancer and metastatic prostate cancer.
Fibroblast growth factor 18 in CIR – one of a family of proteins involved in stimulating cellular growth proliferation and cellular differentiation. In this Phase II study, FGF 18 shows potential as the first disease-modifying drug for cartilage repair. It induces cartilage repair via chondrocyte stimulation, leading to matrix synthesis and chondrocyte renewal.
Atacicept (TACI-Ig) in SLE – atacicept is a recombinant fusion protein, which blocks the cytokines APRIL and BLyS, two members of the tumor necrosis factor family, that regulate B-cell maturation, function, and survival.. A Phase II trial is ongoing in patients with systemic lupus erythematosus (SLE).
